All locations
| Company | Sector & Purpose | Updated | Following |
|---|---|---|---|
|
Abbvie
|
Biopharmaceutical
To discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow
|
2025-Q2
|
|
|
Abbott Laboratories
|
Healthcare
To help people live their best possible life through the power of health
|
2025-Q3
|
|
|
Amgen
|
Biotechnology
To serve patients by transforming the promise of science and biotechnology into therapies with the potential to restore health or save lives
|
2025-Q3
|
|
|
Alnylam Pharmaceuticals
|
Biotechnology
To transform the lives of people afflicted with rare genetic diseases by translating RNA interference into a whole new class of innovative medicines
|
2025-Q3
|
|
|
Amer Vanguard
|
Agricultural Chemicals
To provide innovative crop protection and enhancement solutions that enable farmers to maximize agricultural productivity and feed the world sustainably
|
2025-Q3
|
|
|
Amicus Therapeutics
|
Biotechnology
To serve patients, families and caregivers affected by rare and orphan diseases
|
2025-Q3
|
|
|
3m
|
Industrial Conglomerate
Apply science to improve lives and help solve the world's toughest challenges
|
2025-Q3
|
|
|
Advanced Drainage Systems
|
Water Infrastructure
To provide innovative water management solutions that protect and enhance the environment while supporting infrastructure development
|
2025-Q3
|
|
|
Acadia Pharmaceuticals
|
Biopharmaceuticals
To advance breakthrough medicines that meaningfully improve the lives of patients with central nervous system disorders
|
2025-Q3
|
|
|
Adma Biologics
|
Biopharmaceuticals
To manufacture, market and develop specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases
|
2025-Q3
|
|
|
Agios Pharmaceuticals
|
Biopharmaceutical
To transform the lives of patients with genetically defined diseases through scientific leadership in cellular metabolism
|
2025-Q3
|
|
|
Akebia Therapeutics
|
Biopharmaceutical
To better the lives of people impacted by kidney disease by advancing innovative therapies
|
2025-Q3
|
|
|
Amphastar Pharmaceuticals
|
Specialty Pharmaceuticals
To develop, manufacture, and market generic and proprietary injectable, inhalation, and intranasal pharmaceutical products
|
2025-Q3
|
|
|
Alector
|
Biotechnology
To develop innovative immunotherapies for neurodegenerative diseases by harnessing the brain's immune system
|
2025-Q3
|
|
|
Absci
|
Biotechnology
To create better biologics through the power of artificial intelligence and synthetic biology
|
2025-Q3
|
|
|
Ani Pharmaceuticals
|
Specialty Pharmaceuticals
To develop, manufacture and market branded and generic prescription pharmaceuticals
|
2025-Q3
|
|
|
Amcor
|
Packaging
To develop and produce responsible packaging solutions that protect products and people
|
2025-Q3
|
|
|
Alkermes
|
Biopharmaceuticals
To develop innovative medicines that make a difference for people living with debilitating diseases
|
2025-Q3
|
|
|
Amneal Pharmaceuticals
|
Generic Pharmaceuticals
To make healthy possible by providing high-quality, affordable generic and specialty pharmaceuticals to improve patient access to essential medications
|
2025-Q3
|
|
|
Advansix
|
Specialty Chemicals
To be the leading producer of Nylon 6 resin and chemical intermediates
|
2025-Q3
|
Page 1 of 4
Showing 1 to 20 of 76 analyses